clinical trial · NCT07161687
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Pfizer·—·active not recruiting·n = 50
Hemophilia A or BMarstacimab
brief summary
A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.
started
Oct 30, 2025
primary completion
Apr 11, 2030
completion
Apr 11, 2030
last updated
Mar 30, 2026
detailed description
The objective of this study is to assess the safety of this drug under actual usage conditions in patients with congenital hemophilia who do not have inhibitors.
The observation period will be up to three years. However, for cases in which administration of the drug is discontinued, information will be collected up to the point of discontinuation.
official title
HYMPAVZI S.C. INJECTION 150 mg Pen SPECIAL INVESTIGATION
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol